PTGX
Protagonist Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$134.27-4.71%
Price as of Jul 20, 2026
PTGX valuation
Protagonist Therapeutics, Inc. valuation
Trailing, forward and enterprise-value multiples for the requested listing.
Forward multiples
- P/E forward
- 47.59x
- P/E 2026E
- 47.35x
- P/E 2027E
- —
- P/E 2028E
- 110.70x
- P/S forward
- 62.47x
Trailing multiples
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 13.17x
- Price / sales
- 116.59x
- Price / cash flow
- -74.04x
Enterprise value
- Enterprise value
- $8.1B
- EV / sales
- 109.33x
- EV / EBITDA
- -71.07x
- EV / EBIT
- -56.84x
- Market cap
- $8.6B
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.